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Introduction: Dysregulation of long noncoding RNAs (lncRNAs) 
has been regarded as a primary feature of several human cancers. 
However, the genome-wide expression and functional significance 
of lncRNAs in non–small-cell lung carcinomas (NSCLC) remains 
unclear. The aim of this study was to identify novel lncRNAs that 
may play an important role in contributing to NSCLC pathogenesis.
Methods: We performed an integrative analysis of two NSCLC 
microarray datasets comprising 165 and 90 patients, respectively. The 
candidate lncRNAs were identified using the GSE19188 dataset, and 
then confirmed in the GSE18842 dataset. In addition, an independent 
cohort of 73 clinical samples was analyzed to validate the selected 
lncRNAs by quantitative real-time polymerase chain reaction analysis.
Results: With microarray gene expression analysis, we identified and 
validated a list of 64 lncRNAs significantly dysregulated in NSCLC 
tumors compared with normal lung tissues; and a panel of 181 
lncRNAs that were specific to histological subtypes of NSCLC (ade-
nocarcinoma, large-cell carcinoma, and squamous cell carcinoma). 
The quantitative real-time polymerase chain reaction analysis of six 
selected lncRNAs in clinical samples further confirmed the results of 
microarray analysis.
Conclusions: We have identified and validated multiple novel lncRNAs 
associated with tumorigenesis and histological differentiation in human 
NSCLC. These lncRNAs could be further exploited for the development 
of useful biomarkers in diagnosis, prognosis, and treatment of NSCLC.
Key Words: Gene expression profiling, Long noncoding RNA, 
Microarray, Non–small-cell lung carcinomas, Quantitative real-time 
PCR.
(J Thorac Oncol. 2015;10: 645–654)
Lung cancer is the leading cause of cancer-related deaths worldwide among both men and women. In 2008, more than 
1.8 million cases were newly diagnosed and approximately 
1.6 million people died from the disease.1 It is responsible 
for more deaths than breast, colon, and prostate tumors com-
bined.1 Based on histopathological presentation, lung cancer is 
sub-divided into four major histological subtypes: small-cell 
lung cancer, squamous cell carcinoma (SCC), adenocarcinoma 
(ADC), and large-cell carcinoma (LCC). The latter three, col-
lectively referred to as non–small-cell lung cancer (NSCLC), 
account for almost 80% of lung cancers.2 Despite advances in 
early detection and standard treatment, NSCLC is often diag-
nosed at an advanced stage and carries a poor prognosis. The 
overall 5-year survival rates including all stages for patients 
with ADC, LCC, and SCC are only 17%, 15%, and 11%, 
respectively.3 Greater knowledge of the molecular origins and 
progression of NSCLC may lead to improvements in the pre-
vention, diagnosis, and treatment of the disease. Gene expres-
sion profiling offers a comprehensive molecular understanding 
of lung cancer that may grant insights into its pathophysiology 
and yield relevant information for subtype classification, stag-
ing, prognosis, and therapeutic decision-making.
Over the past decade, advances in genome-wide analy-
sis of gene expression have revealed far more genomic tran-
scription than previously anticipated, with the majority of the 
genome being transcribed into noncoding RNAs (ncRNAs).4 
The ncRNAs are characterized as three types, long ncRNAs, 
mid-size ncRNAs, and short ncRNAs.5 Although most studies 
on ncRNAs are focused on short ncRNAs, such as microR-
NAs, long noncoding RNAs (lncRNAs) are rapidly gaining 
prominence recently. LncRNAs are generally defined as hav-
ing a size greater than 200 nucleotides.5 They have emerged 
as major players in a broad range of biological processes. 
LncRNAs regulate gene expression at the level of post-
transcriptional processing such as protein synthesis, RNA 
maturation, and transport. They also exert their effects in tran-
scriptional gene silencing through the regulation of chroma-
tin structure.6,7 Dysregulation of lncRNAs is associated with 
many human diseases, including various types of cancers.8 
The well-studied lncRNA MALAT-1 (metastasis-associated 
lung adenocarcinoma transcript 1) was initially found abnor-
mally expressed in metastasizing NSCLC;9 however, it is also 
up-regulated in hepatocarcinoma, breast cancer, pancreatic 
cancer, colorectal cancer, and prostate cancer.10 Even more 
interestingly, lncRNAs are not only potential diagnostic mark-
ers but also potential prognostic markers. Recently, Zhang et 
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al.11 reported that a panel of six lncRNAs (KIAA0495, PART1, 
MGC21881, MIAT, GAS5, and PAR5) can be used to predict 
the overall survival of glioblastoma patients.
In this study, we performed an integrative analysis of two 
microarray datasets aimed to identify novel lncRNA biomark-
ers of NSCLC. The selected lncRNAs were then validated in 
clinical samples by quantitative real-time polymerase chain 
reaction (qRT-PCR). Our findings provide novel information 
on lncRNAs expression profiles that may distinguish NSCLC 
tumors from noncancerous tissues, as well as between differ-
ent subtypes of NSCLC.
MATERIALS AND METHODS
Public Microarray Datasets
NSCLC microarray datasets and corresponding clinical 
data were retrieved from public available ArrayExpress data-
base.12 Gene expression profiling was performed using the 
HG-U133Plus2 microarray (Affymetrix, Santa Clara, CA). The 
recent release of the HG-U133Plus2 microarray offers 54,000 
probe sets for screening 38,500 human genes. Microarray data 
preprocessing was conducted using the R software and pack-
ages from the Bioconductor project.13,14 Raw data were collected 
from CEL files and preprocessed with the Robust Multi-chip 
Average algorithm for background correction, quantile nor-
malization, and median polish summarization.15 After Robust 
Multi-chip Average preprocessing, a set of probe ID-centric 
gene expression values were available for downstream analysis.
LncRNA Profile Mining
To evaluate the lncRNA expressions in the probe 
ID-centric gene expression data, we used an established bioin-
formatics pipeline to retrieve the lncRNAs represented on the 
Affymetrix HG-U133Plus2 microarray, previously described 
by Zhang et al.16 In brief, all transcripts represented on the 
microarray were identified as coding RNAs or ncRNAs based 
on their Refseq IDs and (or) Ensembl IDs. Only the ncRNAs 
were retained and further filtered by removing pseudogenes, 
rRNAs, tRNAs, snRNAs, snoRNAs, and other short ncRNAs. 
Eventually, 2448 annotated lncRNA transcripts with corre-
sponding Affymetrix probe IDs were obtained.
Bioinformatics Analysis
The Significance Analysis of Microarrays (SAM) method 
was used to determine the differentially expressed lncRNAs 
between any two groups.17 For gene expression studies involv-
ing microarrays, it has become common practice to focus on 
control of the false discovery rate (FDR), which estimates the 
expected proportion of incorrect rejections among the rejected 
hypotheses.18,19 To minimize false positives, SAM analysis was 
performed using stringent statistics variables with a FDR below 
0.05, and permutation of 1000. We used the prediction analysis 
of microarrays (PAM) method to construct and validate pre-
dictive lncRNA signatures.20 This method is an adaptation of 
a nearest neighbor classification method that considers models 
with different numbers of genes. The performance of optimized 
signatures was validated by “leave-one-out” cross validation 
within the training set first, then with the validation set.
Patients and Samples
We included 57 NSCLC tumor samples and 16 nontumor 
lung tissues for qRT-PCR analyses. The written informed con-
sent was obtained from all participants. The study was approved 
by the Ethics Committee of Fudan University Shanghai Cancer 
Center, China. Out of the 57 tumors, 35 were ADC, five were 
LCC and 17 were SCC; 28 were in Stage I, 18 in Stage II, eight in 
Stage III, and three in Stage IV. The ADC was poorly differenti-
ated in 16 patients, moderately differentiated in 18 and well dif-
ferentiated in one. SCC was poorly differentiated in 13 patients 
and moderately differentiated in four. LCC was all poorly dif-
ferentiated in five patients. The detailed clinical information 
is provided in Supporting Information File 1 (Supplementary 
Table, SDC 1, http://links.lww.com/JTO/A769).
RNA Extraction and qRT-PCR Experiments
Frozen tissues were grossly dissected into TRIZOL for RNA 
extraction following standard protocols. The mRNA quality was 
assessed by the electrophoresis of total RNA, followed by staining 
with ethidium bromide, which showed two clear rRNA bands of 
28S and 18S. Using a spectrophotometer, the ratio of the absor-
bance of each RNA at 260 and 280 nm (A260:A280) was mea-
sured as an indicator of RNA purity. One microgram of total RNA 
was used for cDNA synthesis with Transcriptor First Strand cDNA 
Synthesis Kit (Roche Diagnostics Corp., Indianapolis, IN). QRT-
PCR was performed on an ABI7500 instrument using FastStart 
Universal SYBR Green Master (Rox) kit (Roche). The Actin Beta 
(ACTB) gene was used as an internal control. Primer sequences 
of target lncRNAs are provided in Supporting Information File 2 
(Supplementary Table, SDC 2, http://links.lww.com/JTO/A770). 
Each lncRNA was run in triplicate. The cycle number for each 
candidate gene was normalized against the cycle number of ACTB. 
The calculation of delta Ct value was performed as follows: ΔCt 
(target) = Ct (target) – Ct (ACTB). The fold changes of target 
lncRNA’s expression intensity in tumors compared with normal 
tissue was further calculated as: fold change (to normal) =2^-{[Ct 
(target) - Ct (ACTB)] - [mean of normal delta Ct]}.
RESULTS
Microarray Datasets Characteristics
Two NSCLC microarray datasets obtained from 
ArrayExpress database were included in this study: GSE19188 
and GSE18842. The GSE19188 dataset contained 91 tumor 
samples and 65 adjacent noncancerous tissue samples that 
were collected from NSCLC patients undergoing lung resec-
tion. Among tumor samples, 45 were ADC, 19 were LCC, and 
27 were SCC. The GSE18842 dataset included 45 NSCLC 
tumors paired with adjacent noncancerous tissue samples. Out 
of the 45 tumors, 14 were ADC and 31 were SCC. A detailed 
description of sample characteristics and clinical variables 
are provided in the original report.21,22 To identify reliable 
lncRNA signatures specific to NSCLC, we adopted a train-
ing-validation approach in this study. The GSE19188 dataset 
with a larger sample size were used as training set to identify 
lncRNA signatures, and the GSE18842 dataset were used as 
independent test set for signatures’ validation. The work flow 
of the entire study is illustrated in Figure 1.
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LncRNA Expression Profiles on 
Affymetrix HG-U133 Plus 2.0 Arrays
According to the approach described by Zhang et al.,16 
2448 probe sets corresponding to 1970 lncRNAs genes were 
identified from the Affymetrix HG-U133 Plus 2.0 arrays. Of 
these, 725 probe sets (510 genes) were annotated as lncRNAs 
by both the Refseq and the Ensembl databases; 512 probe 
sets (379 genes) were annotated only by the Refseq database, 
and 1211 probe sets (1081 genes) were annotated only by the 
Ensembl database. The probe sets that were annotated by both 
databases but had controversial definitions were excluded.
Distinctive lncRNA Expressions between 
Normal and NSCLC Samples
Using the GSE19188 dataset as a training set for discov-
ery, we first compared the lncRNA expression profiles of 65 
normal lung tissues to 91 NSCLC tumors without taking his-
tological information into account. The SAM analysis resulted 
in the identification of 710 lncRNAs that were differentially 
expressed between normal lung tissues and NSCLC tumors at 
FDR less than 0.05. Of these 710 deregulated lncRNAs, 551 
lncRNAs were found to be up-regulated and 159 lncRNAs 
to be down-regulated in NSCLC tumors. The top five most 
up-regulated lncRNAs in NSCLC tumors were LINC00673, 
LOC344887, LOC730101, AFAP1-AS1, and MCM3AP-AS1. 
The top five most down-regulated lncRNAs in NSCLC tumors 
were LINC00312, C14orf132, LINC00968, HOXD-AS1, and 
ADAMTS9-AS2. Using the PAM method, a subset of these 
lncRNAs, 64 out of 710, was identified and able to distinguish 
normal lung tissues from NSCLC tumors with a sensitivity of 
95.6% and a specificity of 98.5% based on “leave-one-out” 
cross validation process (Table 1 and Fig. 2). To confirm the 
64-lncRNA signature performance, we further validated our 
findings using the GSE18842 dataset. Similar distinctions 
between normal and NSCLC samples were observed: two 
out of 45 noncancerous lung tissue samples were misclas-
sified, and all the 45 NSCLC tumor samples were correctly 
classified. The overall performance reached 100% sensitiv-
ity and 95.6% specificity. These results demonstrated that the 
64-lncRNA signature identified here was accurate and reliable 
for discriminating NSCLC tumors from normal lung tissues.
Distinctive lncRNA Expressions 
between NSCLC Subtypes
We then determined whether lncRNAs were differen-
tially expressed between subtypes of NSCLC. Using SAM 
method, we compared the 1970 lncRNAs expression profiles 
of each NSCLC subtype to those of the other two subtypes at 
FDR lower than 0.05. In the comparison between 45 ADC and 
19 LCC samples, a list of 96 lncRNAs were found differen-
tially expressed between two groups. Of these 96 lncRNAs, 18 
had increased and 78 had decreased expression levels in ADC 
tumors relative to LCC tumors. In the comparison between 
45 ADC and 27 SCC samples, 84 differentially expressed 
lncRNAs were identified. Among those lncRNAs, 17 were 
over-expressed and 67 were under-expressed in ADC tumors 
relative to SCC tumors. In the comparison between 19 LCC 
and 27 SCC samples, a set of 67 lncRNAs were found dif-
ferentially expressed between two groups. Among those 
lncRNAs, 48 lncRNAs were over-expressed and 19 lncRNAs 
were under-expressed in LCC tumors relative to SCC tumors. 
In Figure 3, Venn diagram illustrates the pairwise comparisons 
of three lncRNAs lists (181 unique lncRNAs in total) that were 
differentially expressed between subtypes of NSCLC, among 
which four lncRNAs: TP53TG1, TP73-AS1, SOX2-OT, and 
LINC00261 were common between all three comparisons; 17 
lncRNAs were in common between “ADC versus LCC” and 
“ADC versus SCC”; 27 lncRNAs were in common between 
“ADC versus LCC” and “LCC versus SCC”; and 14 lncRNAs 
were in common between “ADC versus SCC” and “LCC ver-
sus SCC”. We also compared the list of 181 lncRNAs with 
the 64 lncRNAs identified from NSCLC versus normal sam-
ples. Interestingly, 23 lncRNAs were found to be overlapped 
between the two lists. The detailed information of 23 lncRNAs 
is provided in Supporting Information File 3 (Supplementary 
Table, SDC 3, http://links.lww.com/JTO/A771).
Because there were no LCC samples in the GSE18842 
dataset, we only performed PAM analysis to identify lncRNAs 
FIGURE 1.  Schematic overview of the work flow. 
lncRNA expression profiles were retrieved from Affymetrix 
HG-U133Plus2 microarray through a bioinformatics 
approach. lncRNA expression analyses were performed in the 
training set (GSE19188) first and then validated in the test set 
(GSE18842). lncRNAs, long noncoding RNAs.
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TABLE 1.  List of 64 Long Noncoding RNAs Differentially Regulated in NSCLC Tumors
ProbeSet Symbol Description Regulation Fold Change
220244_at LINC00312 Long intergenic nonprotein coding RNA 312 Down 5.82
218820_at C14orf132 Chromosome 14 open reading frame 132 Down 4.10
243813_at LINC00968 Long intergenic nonprotein coding RNA 968 Down 3.91
228601_at HOXD-AS1 HOXD cluster antisense RNA 1 Down 3.21
1556364_at ADAMTS9-AS2 ADAMTS9 antisense RNA 2 Down 3.15
228004_at LINC00261 Long intergenic nonprotein coding RNA 261 Down 3.07
232298_at MBNL1-AS1 MBNL1 antisense RNA 1 Down 3.05
219563_at LINC00341 Long intergenic nonprotein coding RNA 341 Down 3.01
1568768_s_at BRE-AS1 BRE antisense RNA 1 Down 2.72
208109_s_at LINC00597 Long intergenic nonprotein coding RNA 597 Down 2.57
1559605_a_at LOC285043 Uncharacterized LOC285043 Down 2.47
239656_at LHFPL3-AS2 LHFPL3 antisense RNA 2 Down 2.23
225381_at MIR100HG mir-100-let-7a-2 cluster host gene (nonprotein coding) Down 2.18
1555847_a_at LOC284454 Uncharacterized LOC284454 Down 2.16
230177_at GTF2H2B General transcription factor IIH, polypeptide 2B (pseudogene) Down 2.09
242332_at FENDRR FOXF1 adjacent noncoding developmental regulatory RNA Down 1.94
229323_at LINC00959 Long intergenic nonprotein coding RNA 959 Down 1.88
215318_at MINOS1P1 Mitochondrial inner membrane organizing system 1 pseudogene 1 Down 1.86
230433_at LOC729970 hCG2028352-like Down 1.84
1564139_at A2M-AS1 A2M antisense RNA 1 Down 1.83
242521_at LOC100505812 Uncharacterized LOC100505812 Down 1.82
1553448_at FLJ34503 Uncharacterized FLJ34503 Down 1.80
238893_at LINC00936 Long intergenic nonprotein coding RNA 936 Down 1.79
229699_at LOC100129550 Uncharacterized LOC100129550 Down 1.78
225724_at FLJ31306 Uncharacterized LOC379025 Down 1.72
231024_at PGM5-AS1 PGM5 antisense RNA 1 Down 1.72
242358_at RASSF8-AS1 RASSF8 antisense RNA 1 Down 1.71
215513_at HYMAI Hydatidiform mole associated and imprinted (nonprotein coding) Down 1.69
1558404_at LINC00622 Long intergenic nonprotein coding RNA 622 Down 1.68
229782_at RMST Rhabdomyosarcoma 2 associated transcript (nonprotein coding) Down 1.66
1557371_a_at LINC00961 Long intergenic nonprotein coding RNA 961 Down 1.62
223740_at AGPAT4-IT1 AGPAT4 intronic transcript 1 (nonprotein coding) Down 1.57
230351_at FGF14-AS2 FGF14 antisense RNA 2 Down 1.56
220364_at EPB41L4A-AS2 EPB41L4A antisense RNA 2 (head to head) Down 1.53
227591_at SH3BP5-AS1 SH3BP5 antisense RNA 1 Down 1.49
1558881_at LINC00924 Long intergenic nonprotein coding RNA 924 Down 1.47
1558711_at FAM13A-AS1 FAM13A antisense RNA 1 Down 1.45
1556588_at C15orf37 Chromosome 15 open reading frame 37 Down 1.44
1570375_at LOC100506585 Uncharacterized LOC100506585 Down 1.43
1556026_at LINC00893 Long intergenic nonprotein coding RNA 893 Down 1.41
224644_at FGD5-AS1 FGD5 antisense RNA 1 Down 1.39
220324_at LINC00472 Long intergenic nonprotein coding RNA 472 Down 1.38
1561666_a_at PSMG3-AS1 PSMG3 antisense RNA 1 (head to head) Down 1.37
227452_at LINC00673 Long intergenic nonprotein coding RNA 673 Up 4.35
241418_at LOC344887 NmrA-like family domain containing 1 pseudogene Up 3.23
213248_at LOC730101 Uncharacterized LOC730101 Up 2.56
223779_at AFAP1-AS1 AFAP1 antisense RNA 1 Up 2.27
220459_at MCM3AP-AS1 MCM3AP antisense RNA 1 Up 1.96
224870_at DANCR Differentiation antagonizing nonprotein coding RNA Up 1.96
242786_at SBF2-AS1 SBF2 antisense RNA 1 Up 1.89
228972_at PITPNA-AS1 PITPNA antisense RNA 1 Up 1.72
Continued
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signature for histological classification between ADC and 
SCC samples based on the GSE19188 dataset. Among the 
84 lncRNAs that were differentially expressed between ADC 
and SCC samples, a subset of 71 lncRNAs was identified and 
able to distinguish between ADC and SCC with an overall 
accuracy of 89% based on “leave-one-out” cross validation 
process (Table 2). Then, we applied the 71-lncRNAs signa-
ture to the GSE18842 dataset. The 71-lncRNAs signature cor-
rectly classified all the 14 ADC samples and 22 out of 31 SCC 
samples, resulting in an overall performance of 80% accuracy. 
Therefore, the lncRNA signatures identified between subtypes 
of NSCLC were likely to be representative.
Clinical Validation of Candidate 
lncRNAs by qRT-PCR Analysis
Microarray data provide a global assessment of tran-
scriptomic variations, but their resolution and accuracy are 
limited in individual gene analyses. QRT-PCR is generally 
considered to be the “standard procedure” assay for measur-
ing individual gene expression and is often used to confirm 
the findings of microarray analyses.23 Hence, we further 
evaluated the expression levels of six lncRNAs that were 
most differentially expressed between NSCLC versus nor-
mal samples, and among NSCLC subtypes by qRT-PCR in 
an independent sample of 57 NSCLC tumors and 16 nor-
mal lung tissues. The six candidate lncRNAs were selected 
by multiple criteria: (1) an average expression intensity 
of greater than 50; (2) the maximum fold change in mean 
expression intensity of greater than 2; and (3) a high-grade 
probe design. Figure 4 shows that the expression level of 
ADAMTS9-AS2, C1401f132, and LINC00312 in NSCLC 
tumors were indeed significantly down-regulated when com-
pared with those in normal lung tissues (p = 0.004, p = 0.003, 
and p = 0.05, respectively), whereas LINC00673 was signifi-
cantly up-regulated in NSCLC tumors compared with normal 
lung tissues (p = 0.05). The corresponding receiver operat-
ing characteristic curves were estimated and are provided in 
Supporting Information File 4 (Supplementary Figure, SDC 
4, http://links.lww.com/JTO/A772). Furthermore, the levels 
of LINC00261 and TP73-AS1 were significantly differently 
expressed in subgroups of NSCLC samples (p = 0.004 and 
p = 0.03, respectively). These results thus supported that 
lncRNA expression profiles determined by microarray and 
qRT-PCR analyses were highly comparable. The differen-
tial expression profile of six candidate lncRNAs in NSCLC 
tumors were confirmed in qRT-PCR data.
DISCUSSION
lncRNAs represent a novel class of regulatory RNA 
molecules. Recently, hundreds of lncRNAs have been dis-
covered, and altered lncRNA expression patterns have been 
correlated with tumorigenesis and malignancy transforma-
tion in various types of cancers.24 However, the potential use 
of lncRNA expression profiling regarding to NSCLC patho-
genesis has not been systematically investigated. To explore 
lncRNA expression profiles in NSCLC, a comprehensive 
profiling method is essential. Recently, Zhang et al.16 have 
revealed that lncRNA profiling could indeed be achieved by 
mining the existing microarray gene expression data because 
a great number of lncRNAs were interrogated on many com-
monly used commercial arrays. The robustness of this mining 
approach has also been demonstrated by other studies.11,25,26 
All these studies highlighted the feasibility of using this reli-
able and readily available mining approach in lncRNA expres-
sion profile studies. Based on this method, in this study, we 
performed lncRNA profiling in two cohorts of NSCLC 
patients obtained from public database. Analyzing the asso-
ciations between lncRNA expression profiles and clinical 
variables of NSCLC patients, we identified and validated a set 
of 64 lncRNAs which were dysregulated in NSCLC tumors 
compared with normal lung tissues, as well as a panel of 181 
lncRNAs differentially expressed between histological sub-
types of NSCLC.
We identified a set of 64 lncRNA signature that was 
accurate and robust for discriminating NSCLC tumors from 
normal lung tissues. Such differentiation signified their 
205833_s_at PART1 Prostate androgen-regulated transcript 1 (nonprotein coding) Up 1.59
235373_at LOC100506314 Uncharacterized LOC100506314 Up 1.59
228275_at LINC00888 Long intergenic nonprotein coding RNA 888 Up 1.59
1555907_at AGAP2-AS1 AGAP2 antisense RNA 1 Up 1.56
236480_at MIR210HG MIR210 host gene (nonprotein coding) Up 1.54
222087_at PVT1 Pvt1 oncogene (nonprotein coding) Up 1.49
1556064_at LOC284926 Uncharacterized LOC284926 Up 1.47
1568987_at MGC57346 Uncharacterized LOC401884 Up 1.43
229870_at LOC644656 Uncharacterized LOC644656 Up 1.43
227424_x_at C21orf119 Chromosome 21 open reading frame 119 Up 1.43
1556180_at LINC00847 Long intergenic nonprotein coding RNA 847 Up 1.43
1559352_a_at MAFG-AS1 MAFG antisense RNA 1 (head to head) Up 1.41
1558046_x_at LOC389906 Zinc finger protein 839 pseudogene Up 1.33
NSCLC, non–small-cell lung cancer.
TABLE 1.  (Continued)
ProbeSet Symbol Description Regulation Fold Change
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potential roles in NSCLC pathogenesis. Although some of 
these lncRNAs have been reported to be aberrantly expressed 
in cancers or other diseases, they have not been studied in 
NSCLC. For example, the LINC00312, also known as ERR-
10 gene was previously found to be negatively correlated with 
tumor size but positively correlated with lymph node metas-
tasis in nasopharyngeal carcinoma.27 In estrogen-responsive 
breast cancer cell lines, overexpression of LINC00312 did 
not affect basal expression levels or transcriptional activity 
of ER-alpha, but it reduced estrogen-stimulated ER-alpha 
activity and expression of estrogen-responsive genes.28 
In our study, LINC00312 was strongly down-regulated in 
NSCLC tumors with an average fold change of 5.8 when 
compared with normal lung tissues. Such significant expres-
sion differences may suggest an important regulatory role 
of LINC00312 in NSCLC formation. RMST was originally 
reported to be overexpressed in the alveolar subtype relative 
to the embryonal subtype of rhabdomyosarcoma.29 RMST was 
found to be down-regulated in NSCLC in our study. Another 
candidate, PVT1 was found to be up-regulated in NSCLC 
tumors when compared with normal lung tissues. This find-
ing was in concordance with the previous reports that PVT1 
may have a oncogenic role by increasing cell proliferation and 
inhibiting apoptosis.30 PVT1 was also found to be amplified 
and overexpressed in ovarian, breast, and gastric cancer.4,30 
PART1 was found to be up-regulated in NSCLC in our study. 
It has been reported that this lncRNA is highly expressed in 
the human prostate gland and may play an important role in 
suppressing prostate carcinogenesis.31 Our analysis also iden-
tified several novel lncRNAs that, so far, have not been impli-
cated in NSCLC or other cancers. For example, LINC00673, 
LOC344887, and LOC730101 were listed as the top three 
up-regulated lncRNAs in NSCLC relative to normal lung tis-
sues. The roles of these lncRNAs in NSCLC pathogenesis are 
presently unclear, and our findings suggest that they deserve 
further studies.
NSCLCs exhibit considerable heterogeneity. The WHO 
classification divides NSCLC into three major histological sub-
types: ADC, LCC, and SCC. Here, by comparing the lncRNA 
expression profiles between subtypes of NSCLC, we identified 
96, 84, and 67 lncRNAs that were differentially expressed in 
the comparisons of “ADC versus LCC,” “ADC versus SCC,” 
and “LCC versus SCC,” respectively. Among the three sets 
of lncRNAs identified four lncRNAs, TP53TG1, TP73-AS1, 
SOX2-OT, and LINC00261, were overlapped, suggesting 
their significant roles in NSCLC morphology. TP53TG1 and 
SOX2-OT exhibited strong up-regulation profiles in SCC 
samples compared with ADC and LCC samples, and may 
thus serve as potential markers to distinguish SCC from other 
subtypes. TP53TG1 was first characterized in a colon cancer 
cell line carrying a highly regulated wild-type TP53 expres-
sion system. Under conditions of cellular stress, expression of 
TP53TG1 was induced in a wild-type TP53-dependent manner, 
indicating that this gene is likely to play an important role in 
the signaling pathway of TP53 and may function in response to 
cellular damage.32 Interestingly, the SOX-OT was also found to 
be up-regulated in NSCLC tumors compared with normal lung 
tissues (p < 0.001). SOX2-OT contains at least five exons. The 
gene SOX2 lies within one of the introns of SOX2-OT.33 SOX2 
has important functions during embryonic development and is 
involved in cancer stem cell maintenance, in which it involves 
in cell growth and tumorigenicity.34 It is one of the four tran-
scription factors, whose over expression can induce pluripo-
tency in both mice and human somatic cells.35 Overexpression 
of SOX2 has been described in all types of lung cancer tissues. 
In particular, amplification and overexpression of SOX2 were 
found to be strongly associated with SCC morphology and 
favorable clinicopathological features in SCCs.36
FIGURE 2.  PAM analysis identified lncRNA signatures to 
distinguish normal lung tissues from NSCLC tumors. Upper 
graph The minimum overall misclassification error was 
observed at a threshold value of 4.31 with 64 lncRNAs. 
Lower graph The profile for misclassification error variation 
for normal lung tissues (indicated as “0”) and NSCLC tumors 
(indicated as “1”) as a function of threshold value and the 
number of genes involved. PAM, prediction analysis of micro-
arrays; lncRNAs, long noncoding RNAs; NSCLC, non–small-
cell lung cancer.
FIGURE 3.  Venn diagram of differentially expressed lncRNAs 
between subtypes of NSCLC. NSCLC, non–small-cell lung 
cancer; SCLC, small-cell lung cancer; SCC, squamous cell 
carcinoma; ADC, adenocarcinoma; lncRNAs, long noncoding 
RNAs.
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TABLE 2.  List of 71 Long Noncoding RNAs Differentially Expressed between Adenocarcinoma and Squamous Cell Carcinoma
ProbeSet Symbol Description Fold Change Overexpression
241418_at LOC344887 NmrA-like family domain containing 1 pseudogene 14.29 SCC
231898_x_at SOX2-OT SOX2 overlapping transcript (nonprotein coding) 4.76 SCC
213248_at LOC730101 Uncharacterized LOC730101 2.70 SCC
1561983_at LOC100996490 Uncharacterized LOC100996490 2.33 SCC
1569582_at LOC201651 Arylacetamide deacetylase (esterase) pseudogene 2.27 SCC
231381_at ESRG Embryonic stem cell related (nonprotein coding) 2.04 SCC
224020_at LINC00626 Long intergenic nonprotein coding RNA 626 1.92 SCC
237591_at LINC00173 Long intergenic nonprotein coding RNA 173 1.85 SCC
239319_at LINC00992 Long intergenic nonprotein coding RNA 992 1.85 SCC
1560679_at LOC100506328 Uncharacterized LOC100506328 1.79 SCC
205833_s_at PART1 Prostate androgen-regulated transcript 1 (nonprotein coding) 1.72 SCC
227452_at LINC00673 Long intergenic nonprotein coding RNA 673 1.69 SCC
231540_at LOC100130691 Uncharacterized LOC100130691 1.67 SCC
224870_at DANCR Differentiation antagonizing nonprotein coding RNA 1.67 SCC
228642_at HOTAIRM1 HOXA transcript antisense RNA, myeloid-specific 1 1.64 SCC
244189_at TTC28-AS1 TTC28 antisense RNA 1 1.59 SCC
242786_at SBF2-AS1 SBF2 antisense RNA 1 1.59 SCC
235373_at LOC100506314 Uncharacterized LOC100506314 1.59 SCC
233934_at LOC349160 Uncharacterized LOC349160 1.54 SCC
1555786_s_at LINC00520 Long intergenic nonprotein coding RNA 520 1.52 SCC
1555907_at AGAP2-AS1 AGAP2 antisense RNA 1 1.45 SCC
221847_at LOC100129361 Chromosome X open reading frame 69-like 1.43 SCC
230882_at DLX6-AS1 DLX6 antisense RNA 1 1.43 SCC
1563088_a_at LOC284837 Uncharacterized LOC284837 1.43 SCC
210886_x_at TP53TG1 TP53 target 1 (nonprotein coding) 1.41 SCC
232579_at JHDM1D-AS1 JHDM1D antisense RNA 1 (head to head) 1.39 SCC
239569_at FZD10-AS1 FZD10 antisense RNA 1 (head to head) 1.37 SCC
229338_at LOC100289361 Uncharacterized LOC100289361 1.37 SCC
1554057_at ASH1L-AS1 ASH1L antisense RNA 1 1.37 SCC
1558195_at LINC00592 Long intergenic nonprotein coding RNA 592 1.37 SCC
206279_at PRKY Protein kinase, Y-linked, pseudogene 1.37 SCC
229014_at NR2F1-AS1 NR2F1 antisense RNA 1 1.37 SCC
1568854_at LINC00240 Long intergenic nonprotein coding RNA 240 1.35 SCC
228972_at PITPNA-AS1 PITPNA antisense RNA 1 1.35 SCC
220263_at SMAD5-AS1 SMAD5 antisense RNA 1 1.33 SCC
220209_at PYY2 Peptide YY, 2 (pseudogene) 1.33 SCC
227424_x_at C21orf119 Chromosome 21 open reading frame 119 1.33 SCC
232512_at SCN3A Sodium channel, voltage-gated, type III, alpha subunit 1.32 SCC
1559240_at LOC100507053 Uncharacterized LOC100507053 1.32 SCC
220352_x_at FLJ42627 Uncharacterized LOC645644 1.32 SCC
233562_at LINC00839 Long intergenic nonprotein coding RNA 839 1.32 SCC
232731_x_at RAMP2-AS1 RAMP2 antisense RNA 1 1.30 SCC
232300_at ADIRF-AS1 ADIRF antisense RNA 1 1.27 SCC
227887_at FOXN3-AS1 FOXN3 antisense RNA 1 1.27 SCC
231089_at LOC100505664 Uncharacterized LOC100505664 1.27 SCC
1555874_x_at MGC21881 Uncharacterized locus MGC21881 1.27 SCC
1558791_at LOC286467 Family with sequence similarity 195, member A pseudogene 1.25 SCC
238557_at CHKB-AS1 CHKB antisense RNA 1 (head to head) 1.25 SCC
1562606_a_at LOC440028 Uncharacterized LOC440028 1.23 SCC
225493_at CCNT1 Cyclin T1 1.20 SCC
222060_at KRT8P12 Keratin 8 pseudogene 12 1.20 SCC
Continued
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Another two lncRNAs, TP73-AS1 and LINC00261 
were observed to be significantly down-regulated in NSCLC 
compared with normal lung tissues (p < 0.001), but strongly 
up-regulated in LCC samples compared with ADC and SCC. 
TP73-AS1 is the antisense of the coding gene TP73, which 
encodes a product that shares significant structural and func-
tional similarities to TP53.37 Global genomic analysis shows 
that up to 70% of protein-coding transcripts have antisense 
partners, and the perturbation of the antisense RNA can alter 
the expression of the sense gene.38 TP73-AS1 covers substantial 
portions of TP73, suggesting that TP73-AS1 may function by 
posttranscriptional regulation of the TP73 gene. LINC00261, 
located in 20p11.21, has been found to be down-regulated 
in gastric and liver cancer.4,37 Another interesting lncRNA is 
KRT8L2. Given the fact that SCC tumors are characterized by 
the high expression of keratin genes and histological evidence 
of keratinization, several coding genes for keratin 5, 6, 13–17, 
and 19 had been reported to be overexpressed in SCCs.22 In 
our study, KRT8L2 was found to be exhibited a strong up-reg-
ulation profile in SCC samples compared with ADC and LCC 
samples. To the best of our knowledge, this is the first study 
that describes an overexpression of keratin-related lncRNA in 
SCC compared with other subtypes.
The microarray analysis revealed differential lncRNA 
expression patterns associated with NSCLC tumorigen-
esis and histological classification, which can have poten-
tial implications in diagnosis and treatment. In addition, the 
differential expression profile of six candidate lncRNAs in 
NSCLC tumors was further validated by qRT-PCR in inde-
pendent clinical samples. At present, treatment of NSCLC 
is based on histopathological features and staging. However, 
pathologically similar tumors with comparable stage show 
dramatically different response to the same therapy. Gene 
expression signatures have shown promise for predicting such 
outcome discrepancies among patients more reliably.39–42 The 
distinctive expression patterns of lncRNAs in ADC, LCC, and 
SCC may potentially aid the development of biomarkers for 
the diagnosis of these tumor subtypes. Furthermore, differ-
ential expression profiles of lncRNAs may also direct future 
development of novel therapies. The progress in the use of 
RNAi-mediated gene silencing for the treatment of differ-
ent diseases is encouraging and provides a straightforward 
approach to selectively silence oncogenic lncRNAs.24 For 
example, targeting human H19 for the treatment of bladder 
cancer with a plasmid-based system was recently advanced by 
successes.43 These approaches could conceivably be adapted 
to target functional lncRNA transcripts in NSCLC.
Our study may have several limitations, such as 
HG-U133 Plus 2.0 arrays represent part but not all of the 
possible lncRNAs present. The lncRNAs candidates identi-
fied here may not represent the complete lncRNA populations 
underlying NSCLC biological behavior. In addition, for many 
of the identified lncRNA genes, information regarding their 
possible biological functions and mechanisms is still limited. 
Although their distinct expression patterns suggest potential 
roles in NSCLC development, direct supporting evidence is 
lacking. Therefore, to accurately and comprehensively elu-
cidate the role of lncRNAs in NSCLC, more comprehensive 
profiling researches are needed.
In conclusion, we have identified and validated multiple 
novel lncRNAs associated with tumorigenesis and histologi-
cal differentiation in human NSCLC. Our findings indicate 
241118_at LINC00462 Long intergenic nonprotein coding RNA 462 1.19 SCC
244374_at TINCR Tissue differentiation-inducing nonprotein coding RNA 1.16 SCC
1564295_at FLJ25917 Uncharacterized LOC401585 1.15 SCC
208287_at HCG9 HLA complex group 9 (nonprotein coding) 1.15 SCC
224588_at XIST X inactive specific transcript (nonprotein coding) 6.45 ADC
223779_at AFAP1-AS1 AFAP1 antisense RNA 1 3.05 ADC
239594_at LOC145837 Uncharacterized LOC145837 2.03 ADC
228004_at LINC00261 Long intergenic nonprotein coding RNA 261 1.8 ADC
230177_at GTF2H2B General transcription factor IIH, polypeptide 2B (pseudogene) 1.68 ADC
228549_at TMEM63A Transmembrane protein 63A 1.5 ADC
238953_at LOC100506325 Uncharacterized LOC100506325 1.41 ADC
213340_s_at TP73-AS1 TP73 antisense RNA 1 1.38 ADC
225214_at LOC100129034 Uncharacterized LOC100129034 1.37 ADC
225724_at FLJ31306 Uncharacterized LOC379025 1.35 ADC
233835_at LOC90246 Uncharacterized LOC90246 1.35 ADC
242649_x_at HMGN2P46 High mobility group nucleosomal binding domain 2 pseudogene 46 1.32 ADC
225584_at HCG18 HLA complex group 18 (nonprotein coding) 1.3 ADC
1564207_at LINC00957 Long intergenic nonprotein coding RNA 957 1.27 ADC
229006_at LOC100507487 Uncharacterized LOC100507487 1.27 ADC
1559050_at HCG27 HLA complex group 27 (nonprotein coding) 1.2 ADC
SCC, squamous cell carcinoma; ADC, adenocarcinoma.
TABLE 2.  (Continued)
ProbeSet Symbol Description Fold Change Overexpression
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the potential roles of lncRNAs in NSCLC, and may provide 
useful information for discovery of new biomarkers and thera-
peutic targets. Future studies will focus on the verifications of 
identified lncRNA signatures and the functional elucidation of 
these lncRNAs.
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